(6-methyl-2-(trifluoromethyl)pyridin-3-yl)methanol | 1452479-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (6-methyl-2-(trifluoromethyl)pyridin-3-yl)methanol
• 英文别名: 3-Pyridinemethanol, 6-methyl-2-(trifluoromethyl)-；[6-methyl-2-(trifluoromethyl)pyridin-3-yl]methanol
• CAS: 1452479-28-5
• 化学式: C₈H₈F₃NO
• 分子量: 191.153
• InChiKey: NXTRQEBBFHPQCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] AROMATIC RING COMPOUND<br/>[FR] COMPOSÉ À NOYAU AROMATIQUE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013125732A1

  公开（公告）日：2013-08-29

  The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种具有GOAT抑制作用的化合物，该化合物用于预防或治疗肥胖等疾病，并具有优异的疗效。本发明的化合物由式(I)表示：其中每个符号如说明书中所定义，或其盐。
• Compounds that modulates AMPA receptor function
  申请人：University College Cardiff Consultants Limited

  公开号：US11298345B2

  公开（公告）日：2022-04-12

  The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

  本发明提供了式 (I) 的化合物：(I)其中A1、A2、R2、R4、B1、B2、X、X1、n、a和b如说明书中所定义，以及包含该化合物的药物组合物和用作药物的化合物。本发明化合物可增强AMPA受体功能，有望用于治疗中枢神经系统疾病，例如治疗抑郁障碍、情绪障碍和与神经精神疾病（如精神分裂症）相关的认知功能障碍。
• AROMATIC RING COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2838891A1

  公开（公告）日：2015-02-25
• AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2838891B1

  公开（公告）日：2017-08-02
• COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION
  申请人：University College Cardiff Consultants Limited

  公开号：US20210113539A1

  公开（公告）日：2021-04-22

  The invention provides compounds of the formula (I): (I) wherein A 1 , A 2 , R 2 , R 4 , B 1 , B 2 , X, X 1 , n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.